4D Molecular Therapeutics, Inc Earning Date (FDMT)

USA |NASDAQ |USD

FDMT Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.28
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $14.58M

4d Molecular Therapeutics, Inc's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

FDMT Earnings Date & History Chart

FDMT Earnings & Revenue Forecast

FDMT Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 3 $-3.68 $-4.32 $-2.88

FDMT Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-3.68 $-3.60 $-2.98

FDMT Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 2 $1.55M $0.00 $3.10M

FDMT Earnings Date & Revenue History

FDMT Earnings History

|
Show More
Show More

FDMT Revenue History

|
Show More
Show More

4d Molecular Therapeutics, Inc Next Earnings Date & Report

FDMT Next Earnings Date & Report Preview: Jun 2022 (FQ)

FDMT's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

4d Molecular Therapeutics, Inc Previous Earnings Dates & Reports

FDMT Previous Earnings Date & Report Recap: Mar 2022 (FQ)

4d Molecular Therapeutics, Inc's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

FDMT Previous Earnings Date & Report Recap: Dec 2020 (FY)

4d Molecular Therapeutics, Inc's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.

FDMT's earnings per share (EPS) was $-9.82.

Revenues were $13.61M, better than the forecast of $13.61M by 0.00%, and up by 94.85% from previous year's revenue.

The company reported a net income of $-56.69M.

4d Molecular Therapeutics, Inc reported a free cash flow of $-51.91M for its fiscal year, compared to $-39.91M a year ago.